PMC full text:
Breast Cancer Res Treat. Author manuscript; available in PMC 2015 Mar 4.
Published in final edited form as:
Breast Cancer Res Treat. 2011 Jun; 127(2): 471–478.
Published online 2010 Oct 19. doi: 10.1007/s10549-010-1173-8Table 2
HR+/HER2− | HER2+ | Triple-negative | χ2 P | |
---|---|---|---|---|
n = 4,961 | n = 2231 | n = 948 | ||
Age at diagnosis, years (mean) | 57.3 | 54.9 | 55.2 | |
Age at diagnosis, grouped years | ||||
0–39 | 345 (52%) | 216 (32%) | 107 (16%) | <0.0001 |
40–49 | 1272 (60%) | 607 (29%) | 238 (11%) | |
50+ | 3344 (62%) | 1408 (26%) | 603 (11%) | |
AJCC stage at diagnosis | ||||
I | 2404 (68%) | 809 (23%) | 324 (9%) | <0.0001 |
II | 1853 (58%) | 922 (29%) | 428 (13%) | |
III | 450 (51%) | 310 (35%) | 120 (14%) | |
IV | 137 (47%) | 112 (39%) | 41 (14%) | |
Unknown | 117 (51%) | 78 (34%) | 35 (15%) | |
SES quintilea | ||||
1st | 316 (54%) | 200 (34%) | 66 (11%) | <0.0001 |
2nd | 640 (56%) | 356 (31%) | 139(12%) | |
3rd | 946 (61%) | 427 (27%) | 184(12%) | |
4th | 1310 (61%) | 591 (27%) | 251 (12%) | |
5th | 1749 (64%) | 657 (24%) | 308 (11%) | |
Grade | ||||
I | 1162 (87%) | 142 (11%) | 34 (3%) | <0.0001 |
II | 2389 (72%) | 759 (23%) | 178 (5%) | |
III | 1111 (38%) | 1140 (39%) | 662 (23%) | |
Other/unknown | 299 (53%) | 190 (34%) | 74 (13%) | |
Diagnosis year | ||||
2002 | 615 (59%) | 289 (28%) | 143 (14%) | 0.01 |
2003 | 674 (59%) | 316 (28%) | 157(14%) | |
2004 | 779 (61%) | 338 (26%) | 160(13%) | |
2005 | 804 (60%) | 387 (29%) | 152 (11%) | |
2006 | 962 (62%) | 434 (28%) | 159 (10%) | |
2007 | 1127 (64%) | 467 (26%) | 177 (10%) | |
Histology | ||||
Ductal | 3533 (58%) | 1840 (30%) | 744 (12%) | |
Lobular | 289 (85%) | 39 (11%) | 13 (4%) | <0.0001 |
Mixed/other | 1139 (68%) | 352 (21%) | 191 (11%) | |
Nativity | ||||
US-born | 1182 (66%) | 405 (23%) | 193 (11%) | |
Foreign-born | 3779 (59%) | 1826 (29%) | 755 (12%) | <0.0001 |
Hospital status | ||||
Public | 3555 (62%) ‘ | 1473 (26%) | 686 (12%) | |
Private | 583 (57%) | 348 (34%) | 96 (9%) | <0.0001 |
Unknown | 823 (59%) | 410 (29%) | 166 (12%) |
HR+/HER2− = ER+ and/or PR+, HER2−; HER2+ = ER±, PR±, and HER2+; Triple-negative = ER−, PR−, and HER2−
aNeighborhood-level socioeconomic status (see “methods”): 1st quintile represents those with the lowest SES and the 5th quintile represents those with the highest SES